Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-814 for Opioid Use Disorder Abuse Liability
NCT02692157Phase 2Withdrawn
- Sponsor
- New York State Psychiatric Institute
- Start
- Feb 2016
- Primary completion
- Jul 2017
- Countries
- 1
01
Overview
A Phase 2 trial of fezolinetant in opioid use disorder (OUD), sponsored by New York State Psychiatric Institute. Planned start Feb 2016; status: withdrawn.
02
Drugs
fezolinetant
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02692157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692157.